Overview

Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.
Phase:
N/A
Details
Lead Sponsor:
Ranbaxy Laboratories Limited
Treatments:
Cefprozil
Cephalosporins